Loading…

Clinical and Economic Outcomes of Diffuse Follicular Center Lymphoma: An Analysis Using the National Inpatient Sample (NIS) - 2021

Background: Diffuse Follicular Center Lymphoma (DFCL) is a subtype of non-Hodgkin lymphoma characterized by malignant transformation of follicular center B-cells. It presents a significant clinical challenge due to its heterogeneity in presentation and outcomes. Understanding the demographic, clinic...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144, p.6295-6295
Main Authors: Rajarajan, Srinishant, Babu, Kalaivani, Chattaraj, Asmi, Ramesh, Nithya, Ramanan, Sruthi P, Correa, Amit, Roy, Arya Mariam, Ayanambakkam Attanathi, Adanma Anji
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Diffuse Follicular Center Lymphoma (DFCL) is a subtype of non-Hodgkin lymphoma characterized by malignant transformation of follicular center B-cells. It presents a significant clinical challenge due to its heterogeneity in presentation and outcomes. Understanding the demographic, clinical characteristics, and economic impacts of DFCL can provide valuable insights for healthcare providers and policymakers to improve patient care and resource allocation. This study aims to analyse these aspects using data from the National Inpatient Sample (NIS), a large, nationally representative database of hospital inpatient stays in the United States. Methods: We identified patients with DFCL using ICD-10 code C82.5. Descriptive statistics and multivariable regression analyses were performed to assess primary and secondary outcomes, adjusting for covariates including age, sex, race, median household income for patient ZIP code, Charlson comorbidity index, weekend admission status, hospital region, teaching status of hospital, and hospital bed size. The primary outcome was in-hospital mortality, while secondary outcomes included hospital length of stay (LOS) and total hospitalization charges (TOTCHG). Results: Out of the 6,666,752 hospitalisations in the sample, 280 were identified with DFCL. Among these patients, 60.71% were male, and 39.29% were female. The racial composition was predominantly white (78.57%), followed by black (3.57%), Hispanic (12.5%), Asian or Pacific Islander (3.57%), and other races (1.79%). The mean age of the DFCL patients was 68.39 years. The in-hospital mortality rate for these patients was 12.5% (95% CI: 5.99%-24.26%). Adjusted logistic regression revealed that age (OR: 2.26, 95% CI: 1.18-4.32, p=0.014) and being treated in a teaching hospitals (OR: 2299.42, 95% CI: 3.21-1648837, p=0.021) were significantly associated with higher mortality. Sex, race, median household income for patient ZIP code, Charlson comorbidity index, weekend admission status, hospital region, and hospital bed size did not significantly predict mortality. Regarding the length of stay, the mean hospital LOS for DFCL patients was 7.57 days (95% CI: 5.61-9.54). Adjusted regression analysis indicated that being treated in hospitals located in the Midwest was associated with a significantly shorter LOS (Coefficient: -8.49, 95% CI: -16.12 to -0.87, p=0.029). Negative findings for LOS suggest that sex, race, median household income for patient ZIP code, Charlson com
ISSN:0006-4971
DOI:10.1182/blood-2024-204450